Page last updated: 2024-08-21

pyrazines and scio-469

pyrazines has been researched along with scio-469 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, KC; Chakravarty, S; Dugar, S; Haghnazari, E; Henson, M; Hideshima, T; Higgins, LS; Kapoun, AM; Kerr, I; Luedtke, G; Ma, JY; Mavunkel, B; Medicherla, S; Navas, TA; Nguyen, AN; O'Young, G; Perumattam, J; Protter, AA; Reddy, M; Schreiner, GF; Stebbins, EG1
Walker, K1

Other Studies

2 other study(ies) available for pyrazines and scio-469

ArticleYear
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Leukemia, 2006, Volume: 20, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; In Vitro Techniques; Indoles; Injections, Intravenous; Leupeptins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2006
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines

2007